Drug Discovery Targeted to the Alzheimer's APP mRNA 5′-Untranslated Region: The Action of Paroxetine and Dimercaptopropanol

Journal of Molecular Neuroscience

Volumn 20, Issue 3, 2003, Pages 267-275

  Payton, Sandra ^a   Cahill, Catherine M ^a   Randall, Jeffrey D ^a   Gullans, Steven R ^a   Rogers, Jack T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; APP 5 untranslated region; Dimercaptopropanol; FDA preapproved drugs; Paroxetine; Therapeutics

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AZITHROMYCIN; CHELATING AGENT; DIMERCAPROL; INTERLEUKIN 1; LUCIFERASE; MESSENGER RNA; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; ANTIINFECTIVE AGENT; PROTEIN SYNTHESIS INHIBITOR;

5' UNTRANSLATED REGION; ALZHEIMER DISEASE; ARTICLE; CELL CULTURE; DRUG APPROVAL; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; GENE EXPRESSION REGULATION; PROTEIN PROCESSING; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; REPORTER GENE; RNA STRUCTURE; RNA TRANSLATION; VALIDATION PROCESS; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

5' UNTRANSLATED REGIONS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CELL LINE, TUMOR; CHELATING AGENTS; DIMERCAPROL; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; HUMANS; LUCIFERASES; PAROXETINE; PROTEIN SYNTHESIS INHIBITORS; RNA, MESSENGER; SEROTONIN UPTAKE INHIBITORS;

EID: 0642309509     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:20:3:267     Document Type: Article

References (24)

1. Arjona A., Pooler A., Lee R., and Wurtman R. (2002) Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. Brain Res. 951, 135.
2. Buxbaum J., Oishi M., Chen H. I., Pinkas-Kramarski R., Jaffe E. A., Gandy S. E., and Geengard P. (1992) Cholinergic agonists and interleukin-1 regulate processing and secretion of the Alzheimer βA4 amyloid precursor. Proc. Natl. Acad. Sci. USA 89, 10,075-10,078.
3. Cao X. and Sudhof T. C. (2001) A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293, 115-120.
4. Cherny R., Atwood C. S., Xilinas M. E., Gray D. N., Jones W. D., McLean C. A., et al. (2001) Treatment with copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 641-642.
5. Chishti M. A., Yang D. S., Janus C., Phinney A. L., Home P., Pearson J., et al. (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 21,562-21,570.
6. Crapper McLachlan D. R., Dalton A. J., Kruck T. P. A., Bell M. Y., Smith W. L., Kalow, W., and Andrews, D. F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337, 1304-1308.
7. Feng Y., Zhang F., Lokey L. K., Chastain J. L., Lakkis L., Eberhart D., and Warren S. T. (1995) Translational suppression by trinucleotide repeat expansion at FMR1. Science 268, 731-734.
8. Fisher A., Michaelson D.M., Brandeis R., Haring R., Chapman S., and Pittel Z. (2000) M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Ann. NY Acad. Sci. 920, 315-320.
9. Horowitz B. Z. and Mirkin D. B. (2001) Lead poisoning and chelation in a mother-neonate pair. J. Toxicol. Clin. Toxicol. 39, 727-731.
10. Janus C., Pearson J., McLaurin J., Mathews P. M., Jiang Y., Schmidt S. D., et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
11. Khan W. A., Sahaa D., Rahmana A., Salama M., Bogaertsa J., and Bennish M. (2002) Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. Lancet 360(9347), 1722-1727.
12. Lim G. P., Yang F., Chu T., Chen P., Beech W., Teter B., et al. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709-5714.
13. Ly B. T., Williams S. R., and Clark R. F. (2002) Mercuric oxide poisoning treated with whole-bowel irrigation and chelation therapy. Ann. Emerg. Med. 39, 312-315.
14. Moechars D. G. M., Kuiperi C., Laenen I., and Van Leuven F. (1998) Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs. Neuroreport 9, 3561-3564.
15. Nilsson L., Rogers J., and Potter H. (1998) The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease. Front. Biosci. 3, 436-446.
16. Poehlsgaard J. and Douthwaite S. (2002) The macrolide binding site on the bacterial ribosome. Curr. Drug Targets Infect. Disord. 2(1), 67-78.
17. Rogers J. T., Randall J. D., Leiter L. M., McPhee J., Cahill C. M., Zhan S. S., Potter H., and Nilsson L. N. (1999) Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J. Biol. Chem. 274, 6421-6431.
18. Rogers J. T., Randall J. D., Cahill C. M., Eder P. S., Huang X., Gunshin H., Leiter L., et al. (2002a) An iron-responsive element type II in the 5′ untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 277, 45,518-45,528.
19. Rogers J. T., Randall J. D., Eder P. S., Huang X., Bush A. I., Tanzi R. E., Venti A., et al. (2002b) Alzheimer's disease drug discovery targeted to the APP mRNA 5′ untranslated region. J. Mol. Neurosci. 19, 77-82.
20. Shaw K. T., Utsuki T., Rogers J., Yu Q. S., Sambamurti K., et al. (2001) Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc. Natl. Acad. Sci. U.S.A. 98, 7605-7610.
21. Svitkin Y. V., Pause A., Haghighat A., Pyronnet S., Witherell G., Belsham G. J., and Sonenberg N. (2001) The requirement for eukaryotic initiation factor 4A (eIF4A) in translation is in direct proportion to the degree of mRNA 5′ secondary structure. RNA 7, 382-394.
22. von Koch C. S., Zheng H., Chen H., Trumbauer M., Thinakaran G., van der Ploeg L. H., et al. (1997) Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol. Aging 18, 661-669.
23. Wasco W., Gurubhagavatula S., Paradis M. D., Romano D. M., Sisodia S. S., Hyman B. T., et al. (1993) Isolation and characterization of APLP2 encoding a homologue of the Alzheimer's associated amyloid beta protein precursor. Nat. Genet. 5, 95-100.
24. Weggen S., Eriksen J. L., Das P., Sagi S. A., Wang R., Pietrzik C. U., et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216.